Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Cambridge Nutritional Sciences plc (CNSL.L)
London, GB
Established in 1987 and headquartered in London, UK, Cambridge Nutritional Sciences plc (formerly Omega Diagnostics Group PLC until its name change in September 2023) is a specialist in the development, manufacturing, and supply of medical diagnostic products. The company primarily operates within the food sensitivity testing market, creating and producing "Foodprint" branded kits designed to detect immune reactions to food. Beyond manufacturing, it provides clinical analysis services directly to the public, clinics, and healthcare professionals, and also offers the "Food Detective" consumer food test. Its diverse client base includes government entities, private hospitals, reference laboratories, nutritionists, naturopaths, and other medical practitioners. Cambridge Nutritional Sciences plc boasts a global presence, serving markets across the United Kingdom, continental Europe, North, South, and Central America, India, various other Asian countries and the Far East, Africa, and the Middle East.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -2.56% | -5.00% | -5.00% | -15.56% | -2.56% | -41.54% | -24.00% | -97.08% | -88.16% | -99.99% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%-14.8% Q3'25: -21.7% (vs Q3'23)
-
EPS growth Medical - Instruments & Supplies: +16.3%+571.4% ★ Q3'25: +41.4% (vs Q3'23)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%-4.1% Q3'25: -23.7% (vs Q3'23)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+19.0% ★ Q3'25: -10.1% (vs Q3'23)
-
ROIC Medical - Instruments & Supplies: +6.0%+23.0% ★ Q3'25: -20.3% (vs Q3'23)
-
Share dilution Medical - Instruments & Supplies: +0.1%+0.1% Q3'25: +0.2% (vs Q3'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.16× ★ Q3'25: -0.90× (vs Q3'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|
| Revenue |
9.77M
est: 9.00M (+8.6%)
|
8.33M
est: 8.30M (+0.4%)
|
7.00M
7.00M – 7.00M
-15.7% YoY
|
| EBITDA |
-73.0K
est: -140.3K (+48.0%)
|
2.20M
est: -129.4K (+1,799.1%)
|
-109.1K
-109.1K – -109.1K
+15.7% YoY
|
| EBIT |
-723.0K
est: -883.1K (+18.1%)
|
1.58M
est: -814.4K (+294.4%)
|
-686.9K
-686.9K – -686.9K
+15.7% YoY
|
| Net Income |
-328.0K
est: -714.8K (+54.1%)
|
1.57M
est: -143.0K (+1,195.4%)
|
-929.3K
-929.3K – -929.3K
-550.0% YoY
|
| SGA |
6.67M
est: 6.29M (+6.0%)
|
5.28M
est: 5.80M (-9.0%)
|
4.89M
4.89M – 4.89M
-15.7% YoY
|
| EPS |
0.00
est: 0.00 (+53.3%)
|
0.01
est: 0.00 (+1,200.0%)
|
0.00
0.00 – 0.00
-550.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-28 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-27 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-26 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-22 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-21 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-20 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-19 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-18 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-15 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-14 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-13 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-12 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-11 | A+ | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-08 | A+ | 5/5 | 4/5 | 4/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-07 | A+ | 5/5 | 4/5 | 4/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-06 | A+ | 5/5 | 4/5 | 4/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-05 | A+ | 5/5 | 4/5 | 4/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-01 | A+ | 5/5 | 4/5 | 4/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-30 | A+ | 5/5 | 4/5 | 4/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-29 | A+ | 5/5 | 4/5 | 4/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-28 | A+ | 5/5 | 4/5 | 4/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-27 | A+ | 5/5 | 4/5 | 4/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-24 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Andrew William Shepherd | Global Ambassador - Life President | 317.2K | male |
| James Cooper | Chief Executive Officer & Executive Director | 193.1K | male |
| Ajay Patel | Chief Financial Officer, Secretary & Executive Director | — | male |
| Iain Alexander James Logan | Group Financial Controller | — | male |
| Motunrayo Oyegunle | Secretary | — | — |
| Prashant Maniar | Managing Director of Omega Dx Asia Pvt Limited | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CNSL.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
